The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is curr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-12-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-impact-of-ribavirin-on-real-world-adherence-rates-in-hepatitis-c-p-peer-reviewed-article-CEOR |
| _version_ | 1819129137804083200 |
|---|---|
| author | Walker DR Juday TR Manthena SR Jing Y Sood V |
| author_facet | Walker DR Juday TR Manthena SR Jing Y Sood V |
| author_sort | Walker DR |
| collection | DOAJ |
| description | David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this study is to examine the impact of pill count on real-world adherence rates in patients treated with SOF + SIM with and without RBV. Methods: This retrospective study assessed composite adherence to SOF and SIM over 12 weeks of treatment for two cohorts of hepatitis C patients: one initiating SOF + SIM therapy, and the other initiating SOF + SIM + RBV therapy. Analyses were conducted using MarketScan® and Optum US commercial pharmacy claims and enrollment data. Adherence was adjusted by treatment regimen, age, sex, co-pay, presence/absence of cirrhosis, treatment history, and Charlson Comorbidity Index. Results: There was a significant difference in composite unadjusted and adjusted adherence rates for SOF and SIM for the SOF + SIM vs SOF + SIM + RBV cohorts based on MarketScan data (unadjusted, 92.6% and 89.7%, respectively; P=0.0423; adjusted, 92.2% and 88.7%, respectively; P=0.0176), but not based on Optum data (unadjusted, 94.8% and 95.6%, respectively; P=0.5618; adjusted, 94.8% and 95.1%, respectively; P=0.8589). In the MarketScan and Optum databases, there were no statistical differences in unadjusted and adjusted adherence rates for SOF. Unadjusted and adjusted adherence rates for SIM were mixed, as they were for composite adherence. Conclusion: The impact of the addition of RBV to SOF + SIM therapy was mixed. The impact of RBV on SOF adherence was not significant in either database. Keywords: adherence, hepatitis C, direct acting antiviral, sofosbuvir, simeprevir, ribavirin |
| first_indexed | 2024-12-22T08:38:56Z |
| format | Article |
| id | doaj.art-a003ac8a3099487b8d0f135033ace1ac |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-22T08:38:56Z |
| publishDate | 2015-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-a003ac8a3099487b8d0f135033ace1ac2022-12-21T18:32:16ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812015-12-012015Issue 163764225017The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevirWalker DRJuday TRManthena SRJing YSood VDavid R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this study is to examine the impact of pill count on real-world adherence rates in patients treated with SOF + SIM with and without RBV. Methods: This retrospective study assessed composite adherence to SOF and SIM over 12 weeks of treatment for two cohorts of hepatitis C patients: one initiating SOF + SIM therapy, and the other initiating SOF + SIM + RBV therapy. Analyses were conducted using MarketScan® and Optum US commercial pharmacy claims and enrollment data. Adherence was adjusted by treatment regimen, age, sex, co-pay, presence/absence of cirrhosis, treatment history, and Charlson Comorbidity Index. Results: There was a significant difference in composite unadjusted and adjusted adherence rates for SOF and SIM for the SOF + SIM vs SOF + SIM + RBV cohorts based on MarketScan data (unadjusted, 92.6% and 89.7%, respectively; P=0.0423; adjusted, 92.2% and 88.7%, respectively; P=0.0176), but not based on Optum data (unadjusted, 94.8% and 95.6%, respectively; P=0.5618; adjusted, 94.8% and 95.1%, respectively; P=0.8589). In the MarketScan and Optum databases, there were no statistical differences in unadjusted and adjusted adherence rates for SOF. Unadjusted and adjusted adherence rates for SIM were mixed, as they were for composite adherence. Conclusion: The impact of the addition of RBV to SOF + SIM therapy was mixed. The impact of RBV on SOF adherence was not significant in either database. Keywords: adherence, hepatitis C, direct acting antiviral, sofosbuvir, simeprevir, ribavirinhttps://www.dovepress.com/the-impact-of-ribavirin-on-real-world-adherence-rates-in-hepatitis-c-p-peer-reviewed-article-CEORadherencehepatitis Csofosbuvirsimeprevirribavirin |
| spellingShingle | Walker DR Juday TR Manthena SR Jing Y Sood V The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir ClinicoEconomics and Outcomes Research adherence hepatitis C sofosbuvir simeprevir ribavirin |
| title | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
| title_full | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
| title_fullStr | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
| title_full_unstemmed | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
| title_short | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
| title_sort | impact of ribavirin on real world adherence rates in hepatitis c patients treated with sofosbuvir plus simeprevir |
| topic | adherence hepatitis C sofosbuvir simeprevir ribavirin |
| url | https://www.dovepress.com/the-impact-of-ribavirin-on-real-world-adherence-rates-in-hepatitis-c-p-peer-reviewed-article-CEOR |
| work_keys_str_mv | AT walkerdr theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT judaytr theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT manthenasr theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT jingy theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT soodv theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT walkerdr impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT judaytr impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT manthenasr impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT jingy impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT soodv impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir |